Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)

Loverro Giuseppe, Guarini Attilio, Di Naro Edoardo, Giacomantonio Loredana, Lavopa Cristina, Liso Vincenzo

Research output: Contribution to journalArticle

Abstract

We have evaluated the best method to assess the ovarian reserve and the ovarian protective effect of GnRH-analog (GnRH-a), in 29 women with Hodgkin's disease (HD) treated with chemotherapy (CHT). The ovarian reserve was studied by measuring the serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), inhibin B, antimullerian hormone (AMH) and the ultrasound antral follicular count (AFC). The patients were randomly treated with or without GnRH-a. At the time of study menstrual function was normal in 21 cases (72.4%), but absent in 8 (27.5%). Mean basal values of FSH, LH, AMH, inhibin B and AFC were normal in patients less than 30 years old and in the group treated four years or less before observation. AFC appeared to be the best marker of reduced ovarian reserve and a combination of AFC-AMH or inhibin B appeared the best predictor. In the GnRH-a group, no women had amenorrhoea, although ovarian reserve assessment was not significantly different from those who were not treated. The time-interval from CHT was the only significant predictor of ovarian function in GnRH-a treated patients. In conclusion, ovarian reserve evaluation, in young patients treated by CHT, can be performed by AFC. GnRH-a treatment does not have a protective effect, but could delay the development of ovarian failure.

Original languageEnglish
Pages (from-to)141-147
Number of pages7
JournalHematology
Volume12
Issue number2
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Hodgkin Disease
Gonadotropin-Releasing Hormone
Anti-Mullerian Hormone
Neoplasms
Follicle Stimulating Hormone
Luteinizing Hormone
Drug Therapy
Therapeutics
Time and Motion Studies
Amenorrhea
Observation
Ovarian Reserve
Antral
Serum
inhibin B

Keywords

  • AMH
  • FSH
  • GnRH-a
  • Inhibin-B
  • LH
  • POF

ASJC Scopus subject areas

  • Hematology

Cite this

Giuseppe, L., Attilio, G., Edoardo, D. N., Loredana, G., Cristina, L., & Vincenzo, L. (2007). Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology, 12(2), 141-147. https://doi.org/10.1080/10245330600954072

Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). / Giuseppe, Loverro; Attilio, Guarini; Edoardo, Di Naro; Loredana, Giacomantonio; Cristina, Lavopa; Vincenzo, Liso.

In: Hematology, Vol. 12, No. 2, 04.2007, p. 141-147.

Research output: Contribution to journalArticle

Giuseppe, L, Attilio, G, Edoardo, DN, Loredana, G, Cristina, L & Vincenzo, L 2007, 'Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)', Hematology, vol. 12, no. 2, pp. 141-147. https://doi.org/10.1080/10245330600954072
Giuseppe, Loverro ; Attilio, Guarini ; Edoardo, Di Naro ; Loredana, Giacomantonio ; Cristina, Lavopa ; Vincenzo, Liso. / Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). In: Hematology. 2007 ; Vol. 12, No. 2. pp. 141-147.
@article{168fd534bf7d4b378ac6eebc26b8b99f,
title = "Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)",
abstract = "We have evaluated the best method to assess the ovarian reserve and the ovarian protective effect of GnRH-analog (GnRH-a), in 29 women with Hodgkin's disease (HD) treated with chemotherapy (CHT). The ovarian reserve was studied by measuring the serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), inhibin B, antimullerian hormone (AMH) and the ultrasound antral follicular count (AFC). The patients were randomly treated with or without GnRH-a. At the time of study menstrual function was normal in 21 cases (72.4{\%}), but absent in 8 (27.5{\%}). Mean basal values of FSH, LH, AMH, inhibin B and AFC were normal in patients less than 30 years old and in the group treated four years or less before observation. AFC appeared to be the best marker of reduced ovarian reserve and a combination of AFC-AMH or inhibin B appeared the best predictor. In the GnRH-a group, no women had amenorrhoea, although ovarian reserve assessment was not significantly different from those who were not treated. The time-interval from CHT was the only significant predictor of ovarian function in GnRH-a treated patients. In conclusion, ovarian reserve evaluation, in young patients treated by CHT, can be performed by AFC. GnRH-a treatment does not have a protective effect, but could delay the development of ovarian failure.",
keywords = "AMH, FSH, GnRH-a, Inhibin-B, LH, POF",
author = "Loverro Giuseppe and Guarini Attilio and Edoardo, {Di Naro} and Giacomantonio Loredana and Lavopa Cristina and Liso Vincenzo",
year = "2007",
month = "4",
doi = "10.1080/10245330600954072",
language = "English",
volume = "12",
pages = "141--147",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)

AU - Giuseppe, Loverro

AU - Attilio, Guarini

AU - Edoardo, Di Naro

AU - Loredana, Giacomantonio

AU - Cristina, Lavopa

AU - Vincenzo, Liso

PY - 2007/4

Y1 - 2007/4

N2 - We have evaluated the best method to assess the ovarian reserve and the ovarian protective effect of GnRH-analog (GnRH-a), in 29 women with Hodgkin's disease (HD) treated with chemotherapy (CHT). The ovarian reserve was studied by measuring the serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), inhibin B, antimullerian hormone (AMH) and the ultrasound antral follicular count (AFC). The patients were randomly treated with or without GnRH-a. At the time of study menstrual function was normal in 21 cases (72.4%), but absent in 8 (27.5%). Mean basal values of FSH, LH, AMH, inhibin B and AFC were normal in patients less than 30 years old and in the group treated four years or less before observation. AFC appeared to be the best marker of reduced ovarian reserve and a combination of AFC-AMH or inhibin B appeared the best predictor. In the GnRH-a group, no women had amenorrhoea, although ovarian reserve assessment was not significantly different from those who were not treated. The time-interval from CHT was the only significant predictor of ovarian function in GnRH-a treated patients. In conclusion, ovarian reserve evaluation, in young patients treated by CHT, can be performed by AFC. GnRH-a treatment does not have a protective effect, but could delay the development of ovarian failure.

AB - We have evaluated the best method to assess the ovarian reserve and the ovarian protective effect of GnRH-analog (GnRH-a), in 29 women with Hodgkin's disease (HD) treated with chemotherapy (CHT). The ovarian reserve was studied by measuring the serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), inhibin B, antimullerian hormone (AMH) and the ultrasound antral follicular count (AFC). The patients were randomly treated with or without GnRH-a. At the time of study menstrual function was normal in 21 cases (72.4%), but absent in 8 (27.5%). Mean basal values of FSH, LH, AMH, inhibin B and AFC were normal in patients less than 30 years old and in the group treated four years or less before observation. AFC appeared to be the best marker of reduced ovarian reserve and a combination of AFC-AMH or inhibin B appeared the best predictor. In the GnRH-a group, no women had amenorrhoea, although ovarian reserve assessment was not significantly different from those who were not treated. The time-interval from CHT was the only significant predictor of ovarian function in GnRH-a treated patients. In conclusion, ovarian reserve evaluation, in young patients treated by CHT, can be performed by AFC. GnRH-a treatment does not have a protective effect, but could delay the development of ovarian failure.

KW - AMH

KW - FSH

KW - GnRH-a

KW - Inhibin-B

KW - LH

KW - POF

UR - http://www.scopus.com/inward/record.url?scp=34247183723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247183723&partnerID=8YFLogxK

U2 - 10.1080/10245330600954072

DO - 10.1080/10245330600954072

M3 - Article

C2 - 17454195

AN - SCOPUS:34247183723

VL - 12

SP - 141

EP - 147

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 2

ER -